SGLT2 Inhibitors Beyond Glycemic Control Toward Precision Therapy: A Narrative Review | ||
| Archives of Pharmaceutical Sciences Ain Shams University | ||
| Articles in Press, Accepted Manuscript, Available Online from 15 November 2025 | ||
| Document Type: Review Article | ||
| DOI: 10.21608/aps.2025.383494.1224 | ||
| Authors | ||
| Ruwan Adel Mokhtar* 1; Neven Mohamed Sarhan1; Haidy E Michel2; Sara M Shaheen3; Ahmed Shawky Elserafy4; samar saad azab5 | ||
| 1Clinical Pharmacy Department, Faculty of Pharmacy, Misr International University (MIU), Cairo, Egypt | ||
| 2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt | ||
| 3Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University | ||
| 4Cardiology department, Faculty of Medicine, Ain Shams University, Cairo, Egypt | ||
| 5pharmacology and toxicology department, faculty of pharmacy, ain shms university | ||
| Abstract | ||
| Heart failure is a complicated syndrome with an array of causes which is associated with reduced cardiac function and highly heterogeneous treatment responses. Recently, there has been no clinical optimization of outcomes due to the intensive reliance on pharmacological therapies which further necessitates the development of personalized treatment approaches. Strides in HF medicine came with the advent of sodium-glucose co-transporter 2 inhibitors (SGLT2Is) such as Dapagliflozin, Empagliflozin and canagliflozin which have shown to be useful in HF due to its cardioprotective property beyond controlling glucose, reducing cardiovascular mortality, and hospitalization. However, it is well documented that responses to treatment with SGLT2Is are heterogeneous and this may be due to genetic polymorphisms affecting important pathways like cardiac function, inflammation, and fibrosis among others. This review explores the effects of SGLT2 inhibitors on cardiac remodeling in heart failure, focusing on left ventricular ejection fraction (LVEF), echocardiographic changes, and fibrosis biomarkers. The review will also highlight the importance of genetic testing in shaping clinical decisions and the management of HF. Such an effort may shift the treatment paradigm of HF patients and significantly improve their prognosis. | ||
| Keywords | ||
| Heart Failure; SGLT2Is; Genetic Polymorphism; Cardiac Fibrosis; Echocardiography; Precision Medicine | ||
|
Statistics Article View: 1 |
||
